Therapy Area Reports

Learn More Payer Insights: RA : Update Bulletin [May 2017]

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent positive opinion from the European Medicines Agency (EMA) for Regeneron/Sanofi’s Kevzara...

Compare
Learn More Hepatitis C Virus KOL Insight: Update Bulletin [May 2017]

This edition presents key opinion leader (KOL) views on recent developments in the hepatitis C virus (HCV) infection market. Topics covered include: Medivir AB communicating an update on the results of its triple...

Compare
Learn More Multiple Sclerosis: Update Bulletin [May 2017]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of multiple sclerosis (MS). Topics covered include expert opinions on: the FDA approval of Ocrevus (ocrelizumab,...

Compare
Learn More Melanoma: KOL Insight: Update Bulletin [May 2017]

This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma announcing that it has withdrawn its New Drug Application (NDA)...

Compare
Learn More Chronic Lymphocytic Leukaemia (CLL): Update Bulletin [May 2017]

Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Coverage includes KOL opinions about the Phase III results...

Compare
Learn More NSCLC: KOL Insight: Update Bulletin [May 2017]

Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for the treatment...

Compare
Learn More AML: KOL Insight: Update Bulletin [May 2017]

This update bulletin presents key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) market. Topics covered include: Novartis receiving US FDA approval for Rydapt (midostaurin)...

Compare
Learn More Cystic Fibrosis: KOL Insight: Update Bulletin [May 2017]

This edition presents key opinion leader (KOL) views on recent developments in the cystic fibrosis market. Topics covered include: Corbus Pharmaceuticals’s announcement of positive data from a Phase II study for...

Compare
Learn More HNSCC: KOL Insight: Update Bulletin [May 2017]

This edition presents key opinion leader (KOL) views on recent developments in the treatment of head and neck small cell carcinoma (HNSCC). Topics covered include: KOL views on the approval of Bristol Myers...

Compare
Learn More Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]

This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market. Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the American Academy...

Compare
Learn More Multiple Sclerosis - Payer Insight: Update Bulletin [April 2017]

Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis...

Compare
Learn More Prostate Cancer: Update Bulletin [April 2017]

Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on the two oral PARP inhibitors (AstraZeneca’s Lynparza [olaparib] and Clovis...

Compare
Learn More Psoriasis: Update Bulletin [April 2017]

This edition presents key opinion leader (KOL) views on recent developments in the moderate to severe psoriasis treatment market. Topics covered include: Janssen Biotech announcing new data from two pivotal Phase III...

Compare
Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight Update Bulletin [March 2017]

Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include; expert opinions on the modification...

Compare
Learn More Age-Related Macular Degeneration (AMD): Update Bulletin [March 2017]

This edition presents key opinion leader (KOL) views on recent developments in the wet age-related macular degeneration (wet AMD) market. Topics covered include: Regenxbio announcing its Investigational New Drug application...

Compare
Learn More Type 2 Diabetes Mellitus: Update Bulletin #2 [March 2017]

This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include; the US Food and Drug Administration (FDA) approval of AstraZeneca’s...

Compare
Learn More Breast Cancer KOL Insight: Update Bulletin [March 2017]

Breast Cancer KOL Insight Update Bulletin #3 [2016]: March 2017 This edition presents KOL views on recent developments in the breast cancer market. Topics include; positive results from two Phase III studies:...

Compare
Learn More Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [March 2017]

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF). Topics covered include; expert opinions on the 12-week Phase II study data published for Prometic’s PBI-4050 as a...

Compare
Learn More Ulcerative Colitis: Update Bulletin [March 2017]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on; Protagonist Therapeutics announcing the...

Compare
Learn More Multiple Myeloma: Update Bulletin [March 2017]

This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of positive results from a planned overall survival (OS)...

Compare

Browse by